Partial thromboplastin time is more predictive of bleeding than anti-Xa levels in heparinized pediatric patients after cardiac surgery

J Thorac Cardiovasc Surg. 2018 Jul;156(1):332-340.e1. doi: 10.1016/j.jtcvs.2018.02.101. Epub 2018 Apr 4.

Abstract

Objectives: Anticoagulation with unfractionated heparin (UFH) after pediatric cardiac surgery can be monitored using either activated partial thromboplastin time (aPTT) or anti-factor Xa activity (anti-Xa). However, correlation of bleeding with either of these laboratory values has not been established. We sought to determine the correlation between bleeding events and aPTT and anti-Xa in patients who undergo anticoagulation after congenital heart surgery.

Methods: We prospectively studied pediatric patients treated with UFH after cardiac surgery over an 11-month period. Bleeding events were prospectively assessed and adjudicated. The highest aPTT and corresponding anti-Xa for the 24 hours before bleeding events were collected to assess for association with bleeding. Statistical analysis was performed using generalized additive logistic regression.

Results: A total of 202 patients received UFH over 1488 patient-days. The median age at surgery was 0.4 years (interquartile range, 0.1-2.2). A total of 45 major or clinically relevant bleeding events were observed. The correlation between aPTT and anti-Xa was of moderate strength (R = 0.58; P < .001). The odds of bleeding increased significantly when aPTT exceeded 150 (odds ratio, 1.71 per 10-second increase in aPTT, 95% confidence interval, 1.21-2.42; P = .003). Anti-Xa was not associated with bleeding (odds ratio, 1.11 per 0.1 IU/mL increase, 95% confidence interval, 0.89-1.29; P = .34).

Conclusions: In heparinized pediatric patients after cardiac surgery, increased risk of bleeding is more closely associated with elevated aPTT levels than elevated anti-Xa levels. In addition to anti-Xa, monitoring of aPTT levels should be considered during titration of UFH in pediatric patients after cardiac surgery.

Keywords: anticoagulation; bleeding; congenital heart disease; heparin; thrombosis.

Publication types

  • Comparative Study
  • Webcast

MeSH terms

  • Age Factors
  • Anticoagulants / administration & dosage
  • Anticoagulants / adverse effects*
  • Biomarkers / blood
  • Blood Coagulation / drug effects*
  • Cardiac Surgical Procedures / adverse effects*
  • Child, Preschool
  • Drug Monitoring / methods*
  • Factor Xa / metabolism*
  • Heart Defects, Congenital / surgery*
  • Heparin / administration & dosage
  • Heparin / adverse effects*
  • Humans
  • Infant
  • Partial Thromboplastin Time*
  • Postoperative Hemorrhage / blood
  • Postoperative Hemorrhage / chemically induced
  • Postoperative Hemorrhage / diagnosis*
  • Predictive Value of Tests
  • Prospective Studies
  • Risk Assessment
  • Risk Factors
  • Thrombosis / blood
  • Thrombosis / diagnosis
  • Thrombosis / etiology
  • Thrombosis / prevention & control*
  • Time Factors
  • Treatment Outcome

Substances

  • Anticoagulants
  • Biomarkers
  • Heparin
  • Factor Xa